Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 08:13 ET | Source: Yamo Pharmaceuticals

Yamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025

Yamo Pharma's Phase 2 data at INSAR 2025 show L1-79 delivers statistically significant and clinically meaningful improvements in core autism symptoms.
July 30, 2024 08:05 ET | Source: Yamo Pharmaceuticals

Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism

Yamo Pharmaceuticals announces positive topline results from Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder
November 20, 2023 08:05 ET | Source: Yamo Pharmaceuticals

Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder

Yamo Pharmaceuticals LLC has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents with autism spectrum disorder (ASD).
January 27, 2022 08:00 ET | Source: Yamo Pharmaceuticals

Yamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum Disorder

New York, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, a clinical stage pharmaceutical company developing a novel therapy for the core symptoms of autism spectrum disorder (ASD), today...
November 10, 2021 14:00 ET | Source: Yamo Pharmaceuticals

Yamo Pharmaceuticals Receives Investment from Autism Impact Fund to Support Phase 2 Study of L1-79 in Autism Spectrum Disorder

New York, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, LLC, a clinical stage pharmaceutical company developing a novel therapy for the core symptoms of the autism spectrum disorder (ASD),...
May 14, 2019 08:01 ET | Source: Yamo Pharmaceuticals

Yamo Pharmaceuticals Presents Results from Phase 2 Study of L1-79 in Adolescents and Young Adult Males with Autism Spectrum Disorder at INSAR 2019

New York , May 14, 2019 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, LLC, a clinical stage pharmaceutical company developing a novel therapy for autism spectrum disorder (ASD), announced the...
May 14, 2018 08:00 ET | Source: Yamo Pharmaceuticals

FDA Grants Fast Track Designation for Yamo Pharmaceutical’s L1-79 in Autism Spectrum Disorder

New York, May 14, 2018 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, LLC, a clinical stage pharmaceutical company developing a novel therapy for autism spectrum disorder (ASD), announced today that the...